ADME Tox Customization

Drug discovery efforts are generating increasingly complex compounds, which present increasing challenges in their analysis by standard methods.

Fifteen, even ten years ago the compounds we were testing were much less challenging than the ones we see today.

Katya Tsaioun, Ph.D.
Chief Scientific Officer, President, Apredica

Apredica excels in testing such difficult compounds. Our scientific team is comprised primarily of scientists with Ph.D. degrees who have many years of drug-discovery experience. This allows us to adapt our protocols and methods to work around nearly any challenge presented by the compounds. For us, these modifications are routine. Typically half of the assays we do involve some sort of modification from the routine methods, either because of client preferences or the requirements of the compound. It also allows us to create novel assays to address unique testing needs.

If your drug-discovery program is generating challenging compounds, Apredica is uniquely well-suited to address the particular challenges posed by those compounds. Those challenges are, by definition, unique. So is your program. Please contact us to discuss them.

Customization Case Studies

Initial ADMET Screen
A drug discovery program was being started. Initial ADMET screen was performed on lead series to address unusual variability in efficacy screening. Rapid plasma metabolism was discovered in a few lead series and the mechanism of compounds' binding to proteins identified using custom-developed method. After the problem was identified, it was addressed by the medicinal chemistry.

Custom Assay Development
A chemical series was suspected to have a potential side effect - shortly before a board meeting. Apredica team was contacted, problem discussed and a solution proposed. A representative compound from lead series was tested in the new assay and found not to cause the undesirable effect. The work was completed in 1 week from customer phone call to delivery of results - in time to present results at the board meeting.

In Vivo Metabolism
Unexpected bioanalytical results were obtained in clinical trials. The parent compound disappeared rapidly in plasma. The metabolic pathway of the compound was unknown. Pharmacokinetic studies were compromised by ex vivo metabolism of the compound. Apredica team working together with customer scientists and clinical CRO uncovered novel ex vivo metabolism pathway. Metabolite was found to be responsible for biological activity. Compound development stopped.

Contact us to learn more about how Apredica's customization capabilities can advance your drug-discovery program.